Drug intelligence / Profile preview

Anti-MICA x CD3

Development stage: Preclinical
Lead developer: Aakha Biologics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Anti-MICA x CD3 is a preclinical-stage bispecific T-cell engager (BiTE) being developed by Aakha Biologics for the treatment of solid tumors. The antibody is designed to simultaneously bind to major histocompatibility complex class I-related chain A (MICA) on tumor cells and CD3 on T cells. By bridging these two targets, the drug redirects T-cell-mediated cytotoxicity specifically against MICA-expressing tumor cells, promoting tumor cell lysis and overcoming tumor immune evasion mechanisms such as MICA shedding.

Targets

CD3 (T-cell surface glycoprotein CD3)MICA (Major histocompatibility complex class I-related protein A)

Beyond the preview

Go deeper on Anti-MICA x CD3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-MICA x CD3.

Explore the full profile